Immunosuppression in kidney transplant recipients with COVID-19 infection - where do we stand and where are we heading?
The appropriate immunosuppressive regimen in kidney transplant recipients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2/COVID-19) infection remains unclear. The impact of direct virus injury complicated by dysregulated hyperimmune response with overwhelming release of various cytokines in COVID-19 infected subjects contributes to the complexity of management. The largest concern of the practicing clinicians at current time is how to tailor maintenance immune-modulating therapy during active viral infection and the efficacy of the soon-to-be upcoming immunization for COVID-19. This targeted review aims to cover most of the current evidence on the effect of key maintenance immunosuppressive agents in COVID-19 infection and proposes a line of management to specific scenarios on this very rapidly evolving subject.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Renal failure - 43(2021), 1 vom: 25. Dez., Seite 273-280 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Daoud, Ahmed [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19; kidney transplant; bamlanivimab; immunosuppression; ivermectin; CNI. |
|---|
| Anmerkungen: |
Date Completed 29.01.2021 Date Revised 10.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1080/0886022X.2021.1876730 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320536149 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320536149 | ||
| 003 | DE-627 | ||
| 005 | 20231225173806.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/0886022X.2021.1876730 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1068.xml |
| 035 | |a (DE-627)NLM320536149 | ||
| 035 | |a (NLM)33491531 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Daoud, Ahmed |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunosuppression in kidney transplant recipients with COVID-19 infection - where do we stand and where are we heading? |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.01.2021 | ||
| 500 | |a Date Revised 10.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The appropriate immunosuppressive regimen in kidney transplant recipients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2/COVID-19) infection remains unclear. The impact of direct virus injury complicated by dysregulated hyperimmune response with overwhelming release of various cytokines in COVID-19 infected subjects contributes to the complexity of management. The largest concern of the practicing clinicians at current time is how to tailor maintenance immune-modulating therapy during active viral infection and the efficacy of the soon-to-be upcoming immunization for COVID-19. This targeted review aims to cover most of the current evidence on the effect of key maintenance immunosuppressive agents in COVID-19 infection and proposes a line of management to specific scenarios on this very rapidly evolving subject | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a COVID-19; kidney transplant; bamlanivimab; immunosuppression; ivermectin; CNI. | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 700 | 1 | |a Alqassieh, Ahmad |e verfasserin |4 aut | |
| 700 | 1 | |a Alkhader, Duaa |e verfasserin |4 aut | |
| 700 | 1 | |a Posadas Salas, Maria Aurora |e verfasserin |4 aut | |
| 700 | 1 | |a Rao, Vinaya |e verfasserin |4 aut | |
| 700 | 1 | |a Fülöp, Tibor |e verfasserin |4 aut | |
| 700 | 1 | |a Soliman, Karim M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Renal failure |d 1995 |g 43(2021), 1 vom: 25. Dez., Seite 273-280 |w (DE-627)NLM012950394 |x 1525-6049 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2021 |g number:1 |g day:25 |g month:12 |g pages:273-280 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/0886022X.2021.1876730 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2021 |e 1 |b 25 |c 12 |h 273-280 | ||